The micro-cap jewellery company, which has been attempting to diversify into pharmaceutical consultancy services since FY23, witnessed a complete operational breakdown in the March quarter. Net sales plummeted 50% quarter-on-quarter to just ₹0.25 crores from ₹0.50 crores in December 2025, whilst simultaneously declining 44.44% year-on-year from ₹0.45 crores. The revenue collapse reflects the company's ongoing struggle to establish a sustainable business model across either of its operating segments.
What makes this quarter particularly alarming is the dramatic shift from profitability to substantial losses despite minimal revenue. The company's profit before tax stood at a staggering negative ₹5.54 crores, suggesting significant one-off charges or exceptional items that have not been disclosed in the available financial statements. This represents a catastrophic reversal from the ₹0.39 crores profit before tax reported in Q4 FY25.
| Quarter | Revenue (₹ Cr) | QoQ Change | Net Profit (₹ Cr) | YoY Change | PAT Margin |
|---|---|---|---|---|---|
| Mar'26 | 0.25 | -50.00% | -4.51 | -1,388.57% | -1,804% |
| Dec'25 | 0.50 | -85.07% | 3.04 | +7,500% | 608% |
| Sep'25 | 3.35 | +2,133.33% | 2.53 | +1,165% | 75.52% |
| Jun'25 | 0.15 | -66.67% | 0.06 | — | 40.0% |
| Mar'25 | 0.45 | — | 0.35 | — | 77.78% |
| Dec'24 | 0.00 | -100.00% | 0.04 | — | 0.0% |
| Sep'24 | 0.30 | — | 0.20 | — | 66.67% |
Financial Performance: Complete Operational Collapse
The fourth quarter results reveal a company in severe distress. Operating profit before depreciation, interest, and tax (excluding other income) stood at a meagre ₹0.05 crores, translating to an operating margin of 20% on the minuscule revenue base. However, the company's reliance on other income of ₹0.18 crores—which actually exceeded operating profit—highlights the fundamental weakness in core business operations.
The quarterly progression paints a picture of extreme volatility and operational instability. After posting exceptional results in September 2025 with revenue of ₹3.35 crores and net profit of ₹2.53 crores, the company's performance has deteriorated precipitously. The December quarter saw revenue collapse by 85.07% to ₹0.50 crores, though the company managed to maintain profitability at ₹3.04 crores, likely supported by extraordinary other income of ₹3.71 crores.
The March quarter's negative profit before tax of ₹5.54 crores against revenue of just ₹0.25 crores suggests the presence of significant exceptional charges, write-offs, or provisions that have not been itemised in the available data. The tax credit of ₹1.03 crores (effective tax rate of 18.59%) provided some relief, but was insufficient to prevent the massive net loss.
Critical Red Flag: Unexplained Loss
The ₹5.54 crores loss before tax on revenue of just ₹0.25 crores represents a loss exceeding 22 times quarterly revenue. This suggests major write-offs, exceptional items, or provisions that raise serious questions about asset quality, contingent liabilities, or business viability. The absence of detailed disclosure on the nature of these charges is deeply concerning for investors.
Operational Challenges: Struggling Business Model
Deep Health AI India's operational metrics reveal a company struggling to find its footing. The average return on equity of 7.89% over the past five years falls well below acceptable standards for a viable business, whilst the average return on capital employed of just 1.96% suggests the company is barely generating returns above the risk-free rate. The latest ROE of 11.59% and ROCE of 14.32%, whilst improved, are based on an unstable and volatile earnings base that makes these figures unreliable indicators of sustainable performance.
The balance sheet as of March 2025 shows shareholder funds of ₹22.36 crores, comprising share capital of ₹4.80 crores and reserves of ₹17.55 crores. The company maintains investments of ₹10.03 crores and current assets of ₹5.06 crores against current liabilities of ₹1.61 crores. Whilst the company operates with zero long-term debt—a positive factor in isolation—the complete absence of productive fixed assets (just ₹0.01 crores) raises questions about the company's ability to generate sustainable operating cash flows.
Employee costs remained minimal at ₹0.06 crores in Q4 FY26, consistent with the company's skeletal operational structure. The sales-to-capital-employed ratio of 0.18 times indicates extremely poor asset utilisation, with the company generating less than 20 paise of revenue for every rupee of capital employed—a damning indictment of operational efficiency.
Quality Concerns
Despite being classified as a "Below Average" quality company with some positive attributes like zero debt and no promoter pledging, the fundamental business quality remains questionable. The company's 5-year sales CAGR of 36.22% is undermined by extreme quarterly volatility, whilst the weak average ROCE of 1.96% and ROE of 7.89% indicate chronic value destruction. The minimal institutional holding of just 0.35% reflects sophisticated investors' lack of confidence in the business model.
Shareholding Pattern: Institutional Exodus
The shareholding pattern reveals a concerning trend of institutional disengagement. Foreign institutional investors reduced their stake from 1.04% in September 2025 to 0.35% by December 2025, maintaining this reduced position through March 2026. This 0.69 percentage point reduction in a single quarter signals institutional investors voting with their feet following deteriorating fundamentals.
| Quarter | Promoter | FII | Mutual Funds | Non-Institutional |
|---|---|---|---|---|
| Mar'26 | 0.03% | 0.35% | 0.00% | 99.62% |
| Dec'25 | 0.03% | 0.35% | 0.00% | 99.62% |
| Oct'25 | 0.03% | 0.35% | 0.00% | 99.62% |
| Sep'25 | 0.08% | 1.04% | 0.00% | 98.87% |
| Jun'25 | 0.08% | 1.04% | 0.00% | 98.87% |
The virtual absence of promoter holding at just 0.03%, held by Prakash Rikhabchand Solanki, is highly unusual and raises governance concerns. The complete absence of mutual fund and insurance company holdings, combined with non-institutional investors controlling 99.62% of equity, indicates this is purely a retail-driven stock lacking institutional credibility or oversight.
Peer Comparison: Underperforming the Sector
Within the gems, jewellery, and watches sector, Deep Health AI India's positioning appears relatively attractive on valuation metrics but deeply concerning on fundamental performance. The company trades at a P/E ratio of 5.38 times trailing twelve-month earnings, significantly below the industry average of 45 times and peers like Rajnish Retail (156.19x) and Zodiac-JRD MKJ (70.22x).
| Company | P/E (TTM) | P/BV | ROE | Div Yield | Debt/Equity |
|---|---|---|---|---|---|
| Deep Health AI | 5.38 | 1.25 | 7.89% | 4.48% | -0.11 |
| Rajnish Retail | 156.19 | 0.60 | 4.92% | — | -0.04 |
| Eighty Jewellers | 23.16 | 1.41 | 6.29% | 0.24% | 0.81 |
| Zodiac-JRD MKJ | 70.22 | 0.42 | 1.04% | — | -0.27 |
| Manoj Jewellers | 4.03 | 0.94 | 27.97% | — | 0.39 |
However, the low P/E multiple reflects not value but rather market scepticism about earnings sustainability. Deep Health AI's ROE of 7.89% trails the sector standout Manoj Jewellers (27.97%) whilst exceeding weaker peers. The company's dividend yield of 4.48%, based on a ₹0.10 per share dividend declared in November 2025, appears attractive but may not be sustainable given the recent massive loss.
Valuation Analysis: Value Trap Territory
Despite appearing inexpensive on traditional metrics, Deep Health AI India exhibits classic "value trap" characteristics. The stock trades at a P/E of 5.38 times and price-to-book of 1.25 times, both seemingly attractive multiples. However, the proprietary Mojo valuation grade has deteriorated from "Very Attractive" in February 2025 to "Very Expensive" currently, reflecting the algorithm's assessment that current multiples fail to capture the deteriorating fundamental reality.
The enterprise value-to-EBITDA multiple of 8.32 times and EV-to-sales of 6.56 times appear elevated for a company with such volatile and declining revenues. The PEG ratio of 0.02 times, whilst mathematically low, is meaningless given the unsustainable nature of historical growth rates. The stock's 78.52% decline from its 52-week high of ₹10.29 to the current ₹2.21 represents not a buying opportunity but rather a fundamental repricing of risk.
Stock Performance: Catastrophic Wealth Destruction
The stock's performance metrics paint a picture of severe and sustained wealth destruction. Deep Health AI India has declined 50.80% over the past year, massively underperforming the Sensex's 8.40% decline by 42.40 percentage points. The underperformance extends across all meaningful timeframes, with the stock generating negative alpha of 62.30 percentage points over two years and a staggering 91.56 percentage points over three years.
| Period | Stock Return | Sensex Return | Alpha | Assessment |
|---|---|---|---|---|
| 1 Week | -3.07% | -0.85% | -2.22% | Underperforming |
| 1 Month | -9.80% | -3.51% | -6.29% | Underperforming |
| 3 Month | -24.57% | -8.01% | -16.56% | Severe Underperformance |
| 6 Month | -74.86% | -12.75% | -62.11% | Catastrophic |
| YTD | -62.41% | -12.26% | -50.15% | Severe Underperformance |
| 1 Year | -50.80% | -8.40% | -42.40% | Massive Underperformance |
| 2 Years | -61.93% | 0.37% | -62.30% | Wealth Destruction |
| 3 Years | -72.58% | 18.98% | -91.56% | Extreme Underperformance |
The stock's risk-adjusted return of -0.73 over the past year, combined with extreme volatility of 69.90%, categorises this as a "High Risk Low Return" investment—the worst possible combination. The stock's beta of 1.50 indicates it is 50% more volatile than the broader market, amplifying downside movements whilst failing to participate in market rallies. The stock trades below all key moving averages, from the 5-day MA (₹2.28) to the 200-day MA (₹4.81), confirming the established bearish trend.
Technical Analysis: Entrenched Bearish Trend
The technical picture remains unambiguously bearish. The stock entered a bearish trend on February 20, 2026, at ₹3.42, and has since declined 35% to current levels. The MACD indicator shows mildly bullish signals on the weekly timeframe but remains bearish on the monthly chart, whilst Bollinger Bands indicate bearish conditions across both timeframes. The stock's position below all moving averages, from the 5-day to the 200-day, confirms strong selling pressure with no signs of stabilisation.
Immediate support sits at the 52-week low of ₹1.65, just 25% below current levels, whilst resistance emerges at the 20-day moving average of ₹2.33. More substantial resistance lies at the 100-day MA of ₹3.34 and the 200-day MA of ₹4.81, both of which appear distant given the current momentum. The delivery volume data shows some increased participation, with delivery percentage rising to 82.44% on May 27, 2026, suggesting genuine selling rather than speculative trading.
Investment Thesis: Multiple Red Flags
The investment thesis for Deep Health AI India is overwhelmingly negative across all four critical parameters of the Mojo framework. The quality grade of "Below Average" reflects weak return ratios, unstable earnings, and minimal institutional validation. The financial trend, whilst classified as "Positive" based on six-month profitability, is rendered meaningless by the massive Q4 loss that post-dates the trend classification. The technical trend remains firmly "Bearish" with no signs of reversal, whilst the valuation grade of "Very Expensive" suggests the market has yet to fully price in the deteriorating fundamentals.
The company's overall Mojo score of 23 out of 100 places it firmly in "Strong Sell" territory, with the algorithm recommending exit for existing holders and complete avoidance for prospective investors. This score reflects the convergence of weak fundamentals, deteriorating financials, bearish technicals, and questionable valuation—a toxic combination rarely seen outside distressed situations.
KEY STRENGTHS
- Zero debt balance sheet with net cash position
- No promoter pledging of shares
- Dividend yield of 4.48% (sustainability questionable)
- Low P/E ratio of 5.38x (reflects earnings concerns)
- Book value of ₹4.29 provides some asset backing
KEY CONCERNS
- Catastrophic Q4 loss of ₹4.51 crores on revenue of ₹0.25 crores
- Extreme revenue volatility with no sustainable business model
- Virtual absence of promoter holding at just 0.03%
- Institutional exodus with FII stake declining from 1.04% to 0.35%
- Weak ROE of 7.89% and ROCE of 1.96% over five years
- Stock down 78.52% from 52-week high with bearish trend intact
- High volatility (69.90%) with negative risk-adjusted returns
Outlook: Critical Monitoring Points
POSITIVE CATALYSTS (Low Probability)
- Disclosure and resolution of exceptional items causing Q4 loss
- Establishment of sustainable revenue stream in either segment
- Increased promoter holding demonstrating confidence
- Return to consistent quarterly profitability
RED FLAGS (High Probability)
- Further deterioration in Q1 FY27 results
- Inability to sustain dividend payments
- Additional institutional selling or complete exit
- Continued revenue volatility and margin compression
- Breach of 52-week low at ₹1.65
The Verdict: Avoid at All Costs
Score: 23/100
For Fresh Investors: Complete avoidance recommended. The combination of catastrophic recent losses, extreme revenue volatility, minimal promoter holding, and institutional exodus creates an unacceptable risk profile. The apparent valuation discount is a value trap, not an opportunity.
For Existing Holders: Immediate exit is advisable despite the 78.52% decline from peak. The Q4 FY26 loss of ₹4.51 crores represents a fundamental deterioration that calls into question business viability. Any remaining value should be salvaged before potential further deterioration. The 4.48% dividend yield is unlikely to be sustainable given recent losses.
Fair Value Estimate: ₹1.50 (32% downside from current ₹2.21), with high probability of testing 52-week low of ₹1.65 in near term
Note— ROCE = (EBIT - Other income)/(Capital Employed - Cash - Current Investments)
⚠️ Investment Disclaimer
This article is for educational and informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence, consider their risk tolerance and investment objectives, and consult with a qualified financial advisor before making any investment decisions.
